Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Kutílek, Štěpán; Plášilová, Ivana; Skálová, Sylva; Bayer, Milan; Ondrušová, Erika

doi:10.14712/18059694.2021.32

Acta Medica > Archive > 2021, Vol. 64 > Issue 3 > Oral Ibandronate Therapy in Three…

Acta Med. 2021, 64: 187-192

https://doi.org/10.14712/18059694.2021.32

Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Štěpán Kutílek^a,b,c, Ivana Plášilová^a,c, Sylva Skálová^a, Milan Bayer^a,d, Erika Ondrušová^a

^aDepartment of Pediatrics, Faculty of Medicine and Faculty Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic
^bDepartment of Pediatrics, Klatovy Hospital, Klatovy, Czech Republic
^cDepartment of Pediatrics, Pardubice Hospital, Pardubice, Czech Republic
^dDepartment of Pediatrics, 3rd Faculty of Medicine and University Hospital Královské Vinohrady, Charles University in Prague, Czech Republic

Received December 13, 2019
Accepted August 12, 2021

Introduction: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. Case Report: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. Conclusion: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.